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Fas on renal parenchymal cells does not promote autoimmune are expressed on activated T cells and on parenchymal
nephritis in MRL mice. tissue [1]. The engagement of FasL with autoreactive T
Background. Although Fas on pancreatic islets promotes cells bearing Fas in peripheral tissues imposes a protec-autoimmune diabetes in mice, the role of Fas expression on
tive barrier that protects tissues from autoimmune de-kidney parenchymal cells during autoimmune disease is un-
struction [1]. Apoptosis induced by the engagement ofknown.
Methods. To determine whether Fas on renal parenchymal Fas-FasL has been a favored explanation for immune
cells promotes autoimmune renal destruction, we compared privilege [2–4]. The expression of FasL in the eye and
apoptosis and pathology in Fas-intact and Fas-deficient kidneys testis is considered instrumental in eliminating activated
in an autoimmune milieu. For this purpose, we transplanted
T cells expressing Fas [2–4]. Conversely, the interactionssingle, normal kidneys from MRL-11 (Fas-intact) mice (3
of Fas-bearing parenchymal cells with FasL displayedmonths of age) into age-matched, congenic MRL-Faslpr (Fas-
on T cells destroy parenchymal cells [5–7]. For example,deficient) recipients after removal of nephritic kidneys. These
Fas-intact kidneys were compared with Fas-deficient nephritic diabetes is accelerated in FasL transgenic nonobese dia-
kidneys. betic (NOD) mice expressing Fas and FasL on pancreatic
Results. There is a progressive increase of FasL on kidney-
b cells [7]. Furthermore, NOD mice lacking Fas (Faslprinfiltrating cells and Fas and FasL on renal parenchymal cells
mutation) are protected from insulitis and diabetes, sug-in MRL-11 kidneys during engraftment (0, 2, 4–6, and 8
gesting that Fas-mediated cytotoxicity is required to in-weeks). By comparison, we detected an increase in FasL in
MRL-Faslpr kidneys (3 to 5 months of age), whereas Fas was itiate destruction of pancreatic b cells [7]. Finally,
not detectable. The engagement of T cells bearing FasL with myoblasts genetically modified to express FasL with allo-
Fas expressing tubular epithelial cells (TECs) induced TEC geneic islets bearing Fas infused under the renal capsule
apoptosis in vitro. However, apoptosis and pathology were
accelerated islet destruction [8]. Thus, the binding ofsimilar in kidneys (MRL-11, 8 weeks postengraftment vs.
FasL to Fas expressed on parenchymal cells may beMRL-Faslpr, 5 months) with equivalent amounts of FasL-infil-
autodestructive in other tissues, including the kidney.trating cells or FasL TECs, regardless of Fas on renal parenchy-
mal cells. Although Fas on pancreatic islets mediates destruction
Conclusion. The expression of Fas on renal parenchymal in experimental diabetes, the consequence of Fas expres-
cells does not increase apoptosis or promote renal disease sion on renal parenchymal cells in autoimmune kidneyin MRL-11 mice. We speculate that the autoimmune milieu
disease has not been established. Fas and FasL interac-evokes mechanisms that mask, counter, or pre-empt Fas-FasL-
tions in the kidney may promote kidney destruction.initiated apoptosis in MRL kidneys.
This concept is based on several findings: (a) kidney
parenchymal cells, including mesangial cells (MCs) and
tubular epithelial cells (TECs), express Fas and FasL inThe binding of Fas with its cognate ligand (FasL) in-
vitro when stimulated with cytokines [9–11]; (b) agonisticduces programmed cell death, apoptosis. Fas and FasL
anti-Fas antibodies induce glomerular cell apoptosis in
mice in vivo [12]; and (c) Fas is upregulated in human1 T.W. and A.S. contributed equally to the manuscript.
renal injury and is associated with apoptosis of renal
Key words: diabetes, apoptosis, autoimmune disease, programmed cell parenchymal cells [13]. However, Fas expression on re-
death, parenchymal tissue. nal parenchymal cells is not a prerequisite for autoim-
mune kidney destruction because the Fas-deficientReceived for publication April 14, 1998
MRL/MPJ-lpr/lpr (MRL-Faslpr) mice spontaneously de-and in revised form September 28, 1998
Accepted for publication October 2, 1998 velop autoimmune lupus nephritis. In MRL-Faslpr mice,
the single gene mutation in Fas (Faslpr mutation) is re- 1999 by the International Society of Nephrology
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Table 2. Induction of intrarenal Fas in the MRL-11 kidneyTable 1. Fas and FasL are induced in the MRL-11 (Fas intact)
kidney transplanted into MRL-Faslpr (Fas deficient) mice transplanted into the MRL-Fas/pr mice
Strain Age months Fas/GAPDH ratioInterstitial/
Transplant Glomerular perivascular
Donor (MRL-11) 3 0
Recipient (MRL-Fas/pr) 3 0Donor Recipient Week Fas FasL Fas FasL
Transplant (MRL-11) 5 0.58
MRL-11 MRL-Fas/pr 2 0 0.5 0/0 0.5/0.5
Fas transcripts in the kidney were detected by semiquantitative PCR using5 1 1 1/1 1/1
GAPDH as an internal standard. Transplanted kidneys after 8 weeks en-MRL-11 MRL-11 2 0 0 0/0 0/0
graftment. N 5 3/group.5 0 0 0/0 0/0
MRL-Fas/pr MRL-11 2 0 0.5 0/0 0.5/0.5
5 0 0 0/0 0.5/0.5
Donor and recipient mice are 3–4 months of age. Fas and FasL were stained Table 3. FasL increases in MRL kidneys with ageby immunoperoxidase method using Ab for each antigen. The intensity of stain-
ing was graded from 0 (none), 0.5 (trace), 1 (mild), 2 (moderate), 3 (maximum). Interstitial/MRL-11-MRL-Fas/pr 2 and 5 weeks post-transplant N 5 1, MRL-11-MRL-
Glomerular perivascular11 2 and 5 weeks post-transplant N 5 2, MRL-Fas/pr-MRL-112 and 5 weeks
post-transplant N 5 2 and 1, respectively. Strain Age months N Fas FasL Fas FasL
MRL-Faslpr 1–2 3 0 0.760.5 0/0 0.760.5/1.060
3–4a 4 0 1.860.5 0/0 1.560.5/1.860.5
5–6 4 0 2.560.5 0/0 2.560.5/2.860.5
MRL–11 1–6 8 0 060 0/0 060 / 060sponsible for defective peripheral deletion of autoreac-
tive T cells via Fas-FasL–initiated apoptosis, resulting in Fas and FasL were stained by immunoperoxidase method using Ab for each
antigen.autoimmune tissue destruction of the kidneys, skin, and
Intensity of the staining was graded from 0 (none), 1 (mild), 2 (moderate), 3
joints [14–17]. Therefore, the absence of Fas converts (maximum). Data are mean 6 sd.
a Age of donor and recipient mice.latent renal injury in the MRL-11 (Fas-intact) strain
into a rapid fulminant autoimmune renal disease [18].
To determine whether the intrarenal expression of Fas
induced by an autoimmune environment could trigger (Santa Cruz, CA, USA), respectively. Monoclonal anti-
apoptosis of renal parenchymal cells and promote auto- bodies detecting CD4 and B220 were purchased from
immune kidney destruction, we transplanted a MRL- PharMingen.
11 (Fas-intact) kidney into a MRL-Faslpr (Fas-deficient)
Kidney transplantationrecipient after removing nephritic kidneys. We now re-
port that the transplanted MRL-11 kidneys are infil- Briefly, mice were anesthetized with isoflurane, and
trated by FasL-bearing T cells and that the expression the donor kidney, ureter, and bladder were harvested
of Fas is induced on renal parenchymal cells. Further- en bloc, including the renal artery with a small aortic
more, we demonstrate that the engagement of FasL on T cuff and the renal vein with a small caval cuff [19]. These
cells with Fas on renal parenchymal cells (TECs) triggers vascular cuffs were anastomosed to the recipient abdom-
apoptosis of TECs. However, the severity of pathology inal aorta and vena cava, respectively, below the level
and the number of apoptotic cells are similar in MRL-11 of the native renal vessels. The total ischemic time aver-
(Fas-expressing) and MRL-Faslpr (Fas-deficient) kidneys aged 35 to 40 minutes. Donor and recipient bladders
with equivalent numbers of FasL bearing infiltrating or were attached dome to dome. The right native kidney
renal parenchymal cells. Thus, Fas on renal parenchymal was removed at the time of transplant, and the left native
cells does not promote kidney damage in MRL mice. kidney was removed through a flank incision four days
later. This microvascular surgical procedure is techni-
cally laborious and difficult, and the survival rate in theseMETHODS
strain combinations is one out of three.
Mice
Evaluation of renal pathologyAutoimmune MRL-Faslpr (H-2k; Fas-deficient) mice
and normal MRL-11 (H-2k; Fas-intact) mice were pur- We evaluated renal pathology in tissue fixed with 10%
chased from the Jackson Laboratory (Bar Harbor, ME, buffered formalin and paraffin-embedded, which was
USA) and were maintained in our animal facility. subsequently stained with hematoxylin and eosin, and
then evaluated by light microscopy. We counted the
Reagents numbers of cells in the (a) glomerular areas of 20 ran-
Tissue culture reagents were purchased from GIBCO domly selected glomeruli and enumerated these as cells/
(Grand Island, NY, USA). 2-Mercaptoethanol was pur- glomerulus, and (b) interstitial mononuclear cells in 10
chased from Sigma (St. Louis, MO, USA). Polyclonal randomly selected fields in the cortex and indicated these
antibodies for murine Fas and FasL were purchased from as cells/field. Finally, we evaluated the perivascular cell
infiltration in 10 interlobular and intralobular arteries,PharMingen (San Diego, CA, USA) and Santa Cruz
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Table 4. Fas intact MRL-11 kidneys transplanted into an autoimmune MRL-Fas/pr recipient do not have an increase in apoptotic cells as
compared to Fas deficient MRL-Fas/pr kidneys
(A) Age months N Glomerular Interstitial Perivascular
Donor (MRL-11) 3 3 0 0 0
Recipient (MRL-Fas/pr) 3 3 0 0 0
Transplant (MRL-11 5 3 1.060.5a 2.861.1a 1.761.0a
MRL-Fas/pr 5–6 7 2.960.7 4.961.0 4.061.0
(B) Age months N MC TEC Infiltrating cells
Transplant (MRL-11) 5 3 0.9%b 1.4%b 1.4%b
MRL-Fas/pr 5–6 4 1.6% 2.0% 2.0%
Transplanted kidneys were removed 8 weeks after engraftment. Apoptotic cells were determined by TUNEL assay. Apoptotic cells counted in 10 randomly
selected fields and 20 random glomeruli (3400); (A) Frozen section, number of apoptotic cells.
a P , 0.0001, Transplant (MRL-11) vs. MRL-Fas/pr
(B) Formalin-fixed paraffin section: percentage of apoptotic MC, TEC or infiltrating cells/total glomerular or tubulointerstitial cells.
b P , 0.05, Transplant (MRL-11) vs. MRL-Fas/pr, Wilcoxon test
grading the number of cell layers surrounding the vessel controls included the replacement of primary antibody
with normal rabbit IgG and blocking the anti-Fas or anti-as follows: 0 5 none, 1 5 less than 5 layers surrounding
less than 50% of the vessel, 2 5 5 to 10 layers surrounding FasL antibody with a tenfold molar excess of the Fas
peptide (Santa Cruz) or the FasL peptide (Santa Cruz),less than 50% of the vessel, 3 5 more than 10 layers. In
addition, renal pathology for the entire kidney was respectively. FasL-positive kidney-infiltrating cells were
counted per field (100 mm3). FasL expression on renalscored as follows: 0 (none), 1 (minimum), 2 (moderate),
3 (maximum). All slides were coded and analyzed by parenchymal cells was scored as follows: 0 (none), 1
(minimum), 2 (moderate), and 3 (maximum). To deter-two individuals.
mine the cell phenotype(s) that expresses FasL in the
Immunohistochemical detection of Fas and FasL donor MRL-11 and MRL-Faslpr kidneys, we stained
dual and sequential sections for FasL and the double-Kidneys were snap-frozen in ornithine carbamoyl-
negative T cells (CD42CD82B2201) expressing the B220transferase (Miles Scientific, Naperville, IL, USA) and
epitope or CD4 T cells using monoclonal antibodies andstored in 2808C. To evaluate the presence of Fas and
the immunoperoxidase technique as previously reportedFasL, we fixed 4 mm kidney sections in 95% ethanol for
[20]. We calculated the percentage of FasL1 CD41 orfive minutes and detected Fas and FasL by the immuno-
B2201 T cells/total number of FasL1-infiltrating cells byperoxidase technique using polyclonal hamster antimu-
counting the number of sequential or dual-stained cellsrine Fas antibody (10 mg/ml) and polyclonal rabbit anti-
per field (100 mm3).murine FasL antibody (1 mg/ml). We analyzed the
expression of Fas and FasL in the donor MRL-11 (Fas-
Polymerase chain reaction analysis of Fas and FasL inintact) kidney transplanted into a MRL-Faslpr (Fas-defi-
renal parenchymal cell culturescient) mouse at different time points, as well as native
female kidneys from MRL-11 mice and MRL-Faslpr To establish that resident cells in the kidney are capa-
ble of expressing Fas and FasL, we measured transcriptsmice at three and five months of age. In addition, we
analyzed Fas and FasL expression on formalin-fixed tis- in isolated cultured TECs from MRL-Faslpr (Fas-defi-
cient) and MRL-11 (Fas-intact) mice using the reversesue to distinguish between kidney-infiltrating and renal
parenchymal cells. Formalin-fixed tissue sections (5 mm) transcriptase-polymerase chain reaction (RT-PCR). Pri-
mary cultures of TECs were isolated from MRL-Faslprwere deparaffinized, microwave treated for 12 minutes
in 10 mm sodium citrate (pH 6.0), and incubated with (Fas-deficient) and MRL-11 (Fas-intact) kidneys as
previously described [21, 22]. Total RNA was extracted20% normal sheep serum for 30 minutes. Tissue sections
were then incubated with polyclonal rabbit antimurine from TECs (passages 4 to 6) using RNAzol B (Tel-
Test, Friendswood, TX, USA), a modification of theFas antibody (5 mg/ml; Santa Cruz) and polyclonal rabbit
antimurine FasL antibody (1 mg/ml; Santa Cruz) in 1% guanidium thiocyanate-phenolchloroform method [23].
RNA was washed with 70% ethanol, resuspended inbovine serum albumin overnight at 48C. Bound primary
antibody was labeled with fluorescein isothiocyanate- diethylpyrocarbonate-treated H2O, and stored at 2808C
until use. Isolated RNA was treated with DNAse Iconjugated sheep antirabbit IgG for one hour, followed
by peroxidase-conjugated sheep anti-fluorescein isothio- (RNAse free) to remove genomic DNA. The reverse
transcription for 5 mg total RNA was performed usingcyanate Fab fragments, and 3-39-diamino-benzidine was
used to detect immunoenzymatic labeling. Specificity a RT-PCR kit (Perkin Elmer, Foster City, CA, USA).
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The complementary DNA product (1 mg) was amplified Detection of Fas-FasL–mediated apoptosis in
MRL-11 tubular epithelial cells in vitroby PCR. Primers spanning two exons (exon 1 and exon
3) were used to detect a 283 bp fragment (59 GCC Tubular epithelial cells from MRL-11 kidneys at two
GCAGGCTGCCCACAC39 and 59 ACAGGTTGGTG months of age, prior to renal injury, were cultured on
TACCCCCAT39) [24]. FasL is amplified by primers 12-well tissue culture plates (Costar, Cambridge, MA,
(sense, GAGAAGGAAACCCTTTCCTG; antisense, USA) at 2 3 105 cells per well. To induce Fas expression,
ATATTCCTGGTGCCCATGAT), which generates a MRL-11 TECs were incubated with interferon-g (IFN-g;
PCR product at 940 bp [25]. Ten microliters of PCR 300 U/ml), tumor necrosis factor-a (TNF-a; 30 ng/ml),
product were analyzed by 2% agarose gel electrophore- and lipopolysaccharide (1 mg/ml) for 36 hours and
sis and was stained with ethidium bromide. We used the washed with phosphate-buffered saline as previously de-
housekeeping gene GAPDH for PCR controls. scribed [15]. Lymphocytes were isolated from Fas-defi-
cient MRL-Faslpr or age-matched FasL-deficient MRL-
Detection of Fas and FasL mRNA transcripts in gld mice lymph nodes at four months of age. It has been
donor and transplanted kidney established that nearly all of these lymphocytes are T
cells (98%) and that a vast majority (85%) are doubleFas and FasL mRNA were detected in total RNA
negative [27]. We cocultured these TECs with the freshlyfrom dissected renal cortices by RT-PCR as described
isolated T cells for an additional 24 hours. Apoptoticearlier here. We used GAPDH as an internal standard
cells were labeled with the TUNEL method and analyzedfor semiquantitative analysis of the PCR amplification
by cytofluorography (FACScan; Beckton Dickinson,and determined the ratio Fas/GAPDH by densitometry
Mountain View, CA, USA). Dead cells and T cells wereusing the software NIH image 1.60.
excluded from analysis by selective gating based on for-
In situ detection of apoptotic cells ward and right-angle scatter. At least 20,000 cells were
analyzed for each sample, and two independent experi-We detected apoptotic cells by enzymatic in situ label-
ments were performed.ing of apoptosis-induced DNA strand breaks [termi-
nal deoxynucleotidyl transferase-mediated dUTP-biotin
Statistical analysisnick end labeling method (TUNEL)] [26]. Frozen sec-
The data represent the means 6se, and statistical sig-tions were fixed in 4% paraformaldehyde for 20 minutes,
nificance was determined by analysis of variance andtreated with 0.1% Triton X-100 in 0.1% sodium citrate
Wilcoxon single-rank analysis.for two minutes on ice, and then labeled with TUNEL
reaction mixture containing terminal deoxynucleotidyl
transferase and fluorescein-labeled nucleotides (Boeh- RESULTS
ringer Mannheim, Mannheim, Germany) for 60 minutes MRL-11 kidneys transplanted into the MRL-Faslpr
at 378C. Incorporated nucleotides were subsequently la- mice express Fas
beled with sheep antifluorescein Fab fragment conju-
In order to determine whether MRL-11 kidneysgated with horseradish peroxidase (1:5; Boehringer
transplanted into MRL-Faslpr mice express Fas, we ana-Mannheim) for 30 minutes at 378C. Bound antibody was
lyzed the expression of Fas mRNA in the transplanted
detected with 3-39-diamino-benzidine (Vector Labora-
and donor MRL-11 and recipient MRL-Faslpr kidneys
tories, Burlingame, CA, USA) to obtain a brown reac- (Fig. 1 and Tables 1 and 2). Fas mRNA was detectable at
tion product. TUNEL-positive cells were considered low levels in the donor kidney and increased dramatically
apoptotic by morphologic criteria, including condensed postengraftment (Fig. 1 and Table 2). MRL-11 kidneys
and fragmented nuclei. The number of apoptotic cells expressed substantially more Fas mRNA (38) at eight-
were evaluated by counting the TUNEL-positive cells in weeks postengraftment as compared with MRL-11 kid-
individual glomeruli or in interstitial/perivascular fields neys prior to transplantation (Fig. 1). By comparison, we
(100 mm2). We used the TUNEL method to detect apo- did not detect Fas mRNA in the recipient MRL-Faslpr
ptotic cells on formalin-fixed tissue and counter stained kidney. In addition, we assessed the intrarenal expression
with periodic acid Schiffs reagent and determined the of Fas in donor, transplant, and recipient kidneys using
percentage of apoptotic renal parenchymal cells/total immunohistochemistry (Fig. 2 and Table 1). In contrast
apoptotic cells in glomeruli and interstitial/perivascular to the low level of Fas mRNA expression in the donor
fields. In addition, we stained formalin-fixed tissue with kidney, we did not detect Fas protein in the donor kidney.
hematoxylin and eosin and counted the number of cells Fas was induced within glomeruli and cortical tubules in
with condensed or fragmented nuclei as apoptotic cells/ the transplanted MRL-11 at five- and eight-weeks, but
total cell number. Two blinded observers scored at least not two-weeks postengraftment (Figs. 2 and 5 and Table
20 randomly selected glomeruli and 10 fields (100 mm2) 1). Of note, Fas was not detected in kidney-infiltrating
cells nor in the recipient MRL-Faslpr kidney (Fig. 2).per specimen.
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infiltrating cells were predominantly double negative
(approximately 60%) and CD41 (approximately 30%)
T cells, as determined by dual or sequential staining.
There was a parallel increase of FasL on renal parenchy-
mal cells in the donor kidney postengraftment (Fig. 4A).
The level of FasL on kidney infiltrating and renal paren-
chymal cells in the MRL-Faslpr strain, already increased
in the recipient kidney at the time of transplant (3 months
of age), rose even further by five months of age (Fig. 4
A, D). As a reference point, the level of FasL in the
donor MRL-11 kidney at eight-weeks postengraftment
was equal to the MRL-Faslpr kidney at five months of
age (Fig. 4 A, C, D).
Renal pathology in the transplanted MRL-11 kidneys
increases in proportion to FasL bearing kidney-
infiltrating T cells and TECs and is independent of the
presence of Fas on renal parenchymal cells
To determine whether Fas in MRL-11 kidneys infil-
trated with FasL-bearing T cells promotes autoimmune
renal injury, we analyzed the histopathology in MRL-
11 kidneys transplanted into the MRL-Faslpr recipients.
Glomerular and interstitial nephritis was induced in
transplanted MRL-11 kidneys (Fig. 5). There was a
progressive increase in the number of cells in the glomer-
ular, interstitial, and perivascular area in the MRL-11
transplant (Fig. 5). The extent of renal pathology at
Fig. 1. Fas mRNA is expressed in the MRL-11 kidneys transplanted eight-weeks postengraftment was equivalent to the
into the MRL-Faslpr mice. Fas mRNA was detected in the donor and MRL-Faslpr kidneys at five months of age (Fig. 5).
transplanted kidney by reverse transcription-polymerase chain reaction.
We compared the numbers of FasL-bearing kidney-Fas mRNA was absent in the MRL-Faslpr kidney. Based on the ratio
of Fas/GAPDH transcripts, there was an increase (38) in Fas mRNA infiltrating cells, Fas-bearing renal parenchymal cells,
in the MRL-11 donor by eight-weeks postengraftment. Data shown and renal pathology in the MRL-11–transplanted and
are representative of two experiments.
the MRL-Faslpr kidneys (Fig. 6 A, B). FasL-bearing kid-
ney-infiltrating cells increased in proportion to the sever-
ity of renal pathology in the MRL-11–transplanted kid-
neys and MRL-Faslpr kidneys (Fig. 6A). Fas expression
To confirm that renal parenchymal cells in MRL-11 progressively increased in the MRL-11–transplanted
mice express Fas, we analyzed TECs using RT-PCR. kidneys between two- and eight-weeks postengraftment
TECs derived from MRL-11 , but not MRL-Faslpr kid- and was not detected in MRL-Faslpr nephritic kidneys
neys, expressed Fas mRNA (Fig. 3). In addition, we (Fig. 6B). Of note, the severity of renal pathology and
established that TECs derived from MRL-11 and MRL- increase in FasL-bearing kidney-infiltrating cells was in-
Faslpr kidneys expressed FasL (940 bp; Fig. 3). dependent of the expression of Fas in the kidney (Fig.
6B). Because the engagement of Fas with FasL each
Increased FasL expression on kidney-infiltrating cells displayed on renal parenchymal cells may lead to fratrici-
and renal parenchymal cells in the MRL-11 kidney dal apoptosis [28], we evaluated apoptosis in renal paren-
transplanted into the MRL-Faslpr recipient chymal cells. The extent of apoptosis increased in pro-
FasL is increased in the kidneys of MRL mice with portion to FasL on renal parenchymal cells was not
increased age and renal disease (Table 3). FasL is pro- dependent on Fas displayed on renal parenchymal cells
gressively increased in the MRL-11 donor kidneys (Fig. 6C).
transplanted into MRL-Faslpr recipients. Kidney-infil-
MRL-Faslpr T cells bearing FasL induce apoptosis intrating cells bearing FasL are not detected in the donor
MRL-11 TECs bearing FasMRL-11 kidney prior to transplantation (3 months of
age; Fig. 4). The numbers of kidney-infiltrating cells bear- We determined whether engagement of Fas on TECs
ing FasL progressively increased between two- and eight- (MRL-11) with FasL-bearing T cells (MRL-Faslpr) in-
duces apoptosis in vitro. IFN-g, TNF-a, and lipopolysac-weeks postengraftment (Fig. 4 A, B, C). These kidney-
Wada et al: Intrarenal Fas does not promote nephritis846
Fig. 2. Fas is induced in the MRL-11 (Fas-intact) kidneys transplanted into MRL-Faslpr (Fas-deficient) recipients. (A) Fas was absent in the
MRL-11 kidney contralateral to the donor (three months of age) prior to transplant. (B) Fas was induced within glomeruli (arrows) and TECs
(arrowheads) in the donor MRL-11 kidneys transplanted into MRL-Faslpr recipients at eight-weeks postengraftment. (C) Fas was not detected
in MRL-Faslpr kidney at five months of age (immunoperoxidase staining; A, B, and C, 3500, respectively).
immunostaining; data not shown) induced apoptosis
(36%; Fig. 7). By comparison, unstimulated TECs, which
did not express Fas cocultured with FasL-bearing T cells
or using Fas-bearing TECs cocultured with T cells lack-
ing FasL (FasL-deficient MRL-gld lymph node cells),
did not induce apoptosis in TECs (4%; Fig. 7). Taken
together, MRL-Faslpr T cells induce apoptosis in MRL-
11 TECs via the Fas-FasL pathway in vitro. In addition,
our results suggest that stimulated TECs undergo apo-
ptosis via Fas-FasL–independent mechanisms, as cocul-
turing stimulated TECs with T cells lacking FasL induced
apoptosis on some TECs (16%; Fig. 7).
The number of apoptotic cells in the kidney is
independent of Fas on renal parenchymal cells
Because we established that MRL-Faslpr T cells induced
apoptosis in MRL-11 TECs via engagement of Fas and
FasL in vitro, we assessed the number of apoptotic cells in
the transplant (MRL-11, 0 to 8 weeks postengraftment),
recipient (MRL-Faslpr, 3 months of age), and MRL-Faslpr
(5 months of age) kidneys (Fig. 6 and Table 4). We identi-
fied apoptotic cells in the transplanted MRL-11 kidney
at eight-weeks postengraftment using two different
methods (Figs. 6C and 8). By comparison, apoptotic cellsFig. 3. Fas transcripts in MRL-11 TECs. Fas cDNA was detected in
were absent in donor MRL-11 and MRL-Faslpr recipi-primary cultures of TECs in MRL-11 and MRL-Faslpr mice by reverse
transcription-polymerase chain reaction using two primers spanning ents taken at the time of transplant (3 months of age).
exon 1 and exon 3. The MRL-11 (Fas-intact) TECs expressed Fas As a reference point, we identified similar numbers of(283 bp). By comparison, MRL-Faslpr (Fas-deficient) TECs did not
apoptotic cells in transplanted kidneys eight-weeks post-express the Fas transcript. In addition, MRL-11 and MRL-Faslpr TECs
expressed FasL cDNA transcripts (940 bp). Data shown are representa- engraftment compared with MRL-Faslpr kidneys at five
tive of two experiments.
months of age (Figs. 6C and 8). Thus, the number of
apoptotic cells in the kidney with equivalent amounts of
FasL-bearing kidney-infiltrating cells or Fas-bearing renal
parenchymal cells (MRL-11 transplant, 8 weeks post-charide induced Fas on nearly all TECs (90% as detected
engraftment, and MRL-Faslpr 5 months of age) did notby immunostaining; data not shown). Fas bearing TECs
increase despite the expression of Fas in the MRL-11–(MRL-11) cocultured with FasL-bearing T cells (de-
rived from MRL-Faslpr lymph node cells, evaluated by transplanted kidneys.
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Fig. 4. FasL is induced in the MRL-11 (Fas-intact) kidneys trans-
planted into the MRL-Faslpr (Fas-deficient) recipient. (A) FasL expres-
sion increased progressively on renal parenchymal and kidney infiltrat-
ing cells in MRL-11 kidneys transplanted into MRL-Faslpr recipients
between two- and eight-weeks postengraftment. The level of FasL on
kidney infiltrating and parenchymal cells in the transplanted MRL-11
kidneys at eight-weeks postengraftment was similar to the MRL-Faslpr
at five months of age [(A) N 5 3 for each group except two-week
postengraftment N 5 1; grade (0 5 none, 1 5 minimal, 2 5 moderate,
3 5 maximum)]. (B) FasL expression in donor MRL-11 kidney (3660).
(C) MRL-11 kidney eight weeks after postengraftment. Note the FasL
expression on kidney-infiltrating cells (arrows) and TECs (arrowheads;
31330). (D) MRL-Faslpr kidney at five months of age. FasL on kidney-
infiltrating cells perivascular (arrows; 31330).
Surgery does not induce Fas, FasL, or renal injury in field, respectively). Therefore, surgery alone was not re-
sponsible for inducing Fas, FasL, or renal injury in thethe donor MRL-11 kidney
donor MRL-11 kidney.To eliminate the possibility that the surgical complica-
tions related to ischemia and reperfusion induced renal
injury and Fas, we transplanted a kidney from an MRL- DISCUSSION
11 mouse into a bilaterally nephrectomized MRL-11 We now report that Fas and FasL are induced in the
recipient. We did not detect Fas or FasL in the donor Fas-intact MRL-11 kidneys transplanted into congenic
MRL-11 kidney five weeks after postengraftment (data MRL-Faslpr recipients following removal of both ne-
not shown). In addition, we did not note an increase in phritic kidneys. Fas is induced on renal parenchymal
renal pathology (cells in the kidney) at two- or five- cells, including MCs and TECs in the MRL-11–
transplanted kidneys. Furthermore, the engagement ofweeks postengraftment (25 6 6 cells/field vs. 27 6 3 cells/
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to NOD mice, Fas expression on parenchymal cells is
not a prerequisite for autoimmune tissue destruction in
the MRL strain. On the contrary, kidney disease is accel-
erated in Fas-deficient MRL-Faslpr mice as compared
with the Fas-intact MRL-11 strain (50% mortality at 5
and 17 months of age, respectively). This suggests that
pathways other than Fas are responsible for apoptosis
in MRL kidneys. Thus, it is not entirely surprising that
neither an increase in apoptotic cells nor kidney damage
is enhanced when a Fas-intact MRL kidney is trans-
planted into an autoimmune kidney-destructive environ-
ment. We suggest that the factors that govern Fas-medi-
ated destruction of parenchymal cells in the kidney differ
from the thyroid and pancreatic b cells.
Our evidence that Fas bearing MCs and TECs do not
contribute to autoimmune kidney destruction is novel.
Because (a) Fas and FasL are expressed on MCs and
TECs, (b) FasL-bearing T cells induce apoptosis of Fas-
bearing TECs in vitro, and (3) injecting agonistic anti-
Fas antibody induces apoptosis in glomerular cells in
normal mice [17], we anticipated that Fas expression on
renal parenchymal cells would accelerate kidney destruc-
tion in MRL-11 mice. However, renal pathology and
apoptosis were similar in Fas-intact and Fas-deficient
kidneys, with equivalent levels of kidney-infiltrating
FasL-bearing T cells. How can we explain this apparent
paradox? There are multiple possible reasons. First, Fas
expression on cells does not necessarily lead to apoptosis.Fig. 5. Glomerular and interstitial nephritis was induced in trans-
planted MRL-11 kidneys. The number of cells within glomerular, Fas-mediated apoptosis depends not only on the expres-
interstitial, and perivascular areas progressively increased in the MRL-
sion of Fas, but also on the presence of “survival” factors,11 kidney transplanted into MRL-Faslpr recipients between two- and
such as Bcl-xL, Bcl-2, and Fas-associated phosphatase-1eight-weeks postengraftment. The extent of renal pathology at eight-
weeks postengraftment was equivalent to the MRL-Faslpr kidneys at [32–34]. It is possible that TECs express survival factors
five months of age [hematoxylin and eosin, cells/field (100 mm3)].
that spare them from destruction. Second, the autoim-
mune milieu of MRL-Faslpr mice may provide molecules
that mask or counter the engagement of Fas-FasL. For
example, circulating anti-FasL autoantibodies in patientsFasL on T cells with Fas on TECs induces apoptosis of
TECs in vitro. Nevertheless, apoptosis and renal pathol- with systemic lupus erythematosus inhibit Fas-FasL–
mediated apoptotic cell death of lymphocytes in vitroogy were similar in kidneys with equivalent amounts
of FasL-bearing kidney-infiltrating cells or FasL-bearing [35]. In addition, FasL can be cleaved to produce a solu-
ble form that blocks cytotoxicity of the membrane-boundTECs (MRL-11 8 weeks postengraftment vs. MRL-
Faslpr 5 months of age), regardless of Fas on renal paren- FasL [36]. Third, engagement of molecules on T cells
other than FasL may deliver a signal to induce TECchymal cells (MRL-11). Thus, Fas on renal parenchy-
mal cells, at least in the MRL strains, does not promote apoptosis. We have previously established that the pro-
gression of kidney disease in Fas-deficient MRL-Faslprautoimmune kidney damage.
Tissues undergoing autoimmune attack express Fas mice is associated with an increase in apoptotic cells
within the nephritic kidney [37]. In fact, we have notedand FasL [29–31]. The expression of Fas on parenchymal
cells may deliver a lethal signal [5, 6]. For example, Fas that FasL-deficient MRL T cells induced apoptosis in
some activated TECs (16%) in vitro. In addition, weand FasL expression on Hashimoto’s thyroiditis thyro-
cytes results in massive thyrocyte apoptosis [6]. Similarly, established that IFN-g induces TEC apoptosis and renal
injury in the MRL-Faslpr mice [37]. Furthermore, othersFas-mediated cytotoxicity initiates b islet cell destruction
in the autoimmune diabetic NOD strain [5]. In fact, the recently reported that perforin and granzyme B interac-
tions predominate over Fas-FasL engagement in initiat-Fas-deficient NOD strain (NOD-Faslpr) remains normal
and is protected from insulitis and diabetes [7]. We now ing human TEC apoptosis, at least in vitro [38]. Thus, it
is conceivable that kidney-infiltrating T cells in the MRLreport Fas and FasL expression in MRL-11 kidneys
during autoimmune destruction. However, as opposed strains release molecules that induce renal injury and
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b
Fig. 6. Renal pathology and apoptosis in transplanted MRL-11 kid-
neys increases in proportion to FasL-bearing kidney-infiltrating T cells
and is independent of the presence of Fas on renal parenchymal cells.
(A) FasL-bearing kidney-infiltrating cells ( ) increased in proportion
to the severity of renal pathology ( ) in the MRL-11–transplanted
kidneys and MRL-Faslpr kidneys. (B) Fas expression progressively in-
creased in the MRL-11–transplanted kidneys between two- and eight-
weeks postengraftment and was not detected in MRL-Faslpr nephritic
kidneys. Symbols are: ( ) Fas (parenchymal cells); ( ) renal pathol-
ogy. (C) Similar numbers of apoptotic cells were detected in trans-
planted kidneys eight weeks post-engraftment compared with MRL-
Faslpr kidneys at five months of age using two different methods: ( )
TUNEL; ( ) morphology. For (A) and (B), FasL bearing cells, Fas
expression and pathology graded on a 0 to 3 scale (0 5 none, 1 5
minimal, 2 5 moderate, 3 5 maximum). For (C), the percentage of
apoptotic cells/total cell number counted per 100mm3 field. N 5 3 for
each group except two weeks post-transplant N 5 1.
Fig. 7. MRL-Faslpr T cells induce apoptosis in MRL-11 TECs via
the Fas-FasL pathway. Cultured TECs from MRL-11 kidneys were
stimulated to express Fas using a combination of cytokines IFN-g (300
U/ml), TNF-a (30 ng/ml), lipopolysaccharide (1 mg/ml) ( ) and were
then cocultured with Fas-deficient MRL-Faslpr ( ) or age-matched
FasL-deficient MRL-gld ( ) freshly isolated lymph node T cells. Apo-
ptotic cells were detected with the TUNEL method and using FACS
analysis as described in the Methods section. Data represent the mean
of two independent experiments, sem , 5%, P , 0.001 MRL-Faslpr T
cells vs. MRL-gld T cells on stimulated and unstimulated MRL-11 TECs.
apoptosis in renal parenchymal cells and pre-empt Fas-
FasL interactions. We are currently designing experi-
ments to identify the molecular events that mask,
counter, or pre-empt Fas-mediated renal parenchymal
cell death.
It is important to note that there are at least two mouse
FasL allotypes. MRL-Faslpr mice express FasL.1, and the
specific activity of FasL.1 is substantially lower than
FasL.2 expressed by BALB/c and other mouse strains
[39]. Thus, Fas-FasL interactions may be more potent
in other strains and forms of kidney disease. It remains
to be established whether the expression of Fas-FasL
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